With an impressive achievement of growing the novel “flexible solutions” business unit by an astounding 50 percent in his first year of spearheading the region, Ricardo Uribe, Covance Mexico’s Director of Country Operations, shares his insights into the attractiveness of the region for clinical research. He speaks about the impressive 10-year leadership stance of the company in the market, the suitability of the epidemiological profile of the region, as well as the crucial role that CROs play in creating a sustainable healthcare system.
Covance is the world’s most comprehensive drug development company. Can you please a brief overview and history of the Mexican Covance affiliate, as well as the activities wider Central American and Caribbean region?
"The decision to contract research activities to a CRO is typically driven by both the quality that the sponsor will receive and the cost-saving prospect of no longer needing to hire long-term employees in-house."
